Jessica Hagen
Jessica Hagen is an Editor at MobiHealthNews. She covers the growth of digital health, including the medical extended reality (XR) industry, and reports in-depth on the pharmaceutical and biotechnology sectors. As a hobby, Jessica co-hosts a podcast with Dr. Kim Bullock, a medical XR pioneer at Stanford University, about immersive technology use in psychiatric care. She received a bachelor's degree in English with a minor in Journalism from California State University, Northridge.
10:30 am
July 17, 2024
The app Fitterfly Klik allows people with diabetes to analyze their meals using a picture and AI that examines portion size, calorie count, and macronutrients and micronutrients.
10:25 am
July 16, 2024
Teladoc will integrate Brightline's pediatric, adolescent and family mental healthcare services into its virtual care platform, expanding care access to individuals zero to 13.
12:45 pm
July 03, 2024
The virtual care company will be directly available to patients experiencing menopause and perimenopause or via a Keck Medicine of USC-affiliated provider.
12:49 pm
June 26, 2024
Matt Damon, Zac Efron, Kevin Hart, Pedro Pascal and Colin Kaepernick joined Andreessen Horowitz in investing in the whole-body health company.
09:44 am
June 24, 2024
The acquisition will allow the fertility and family-building company to provide its services in more than 100 countries and in over 225 languages.
09:53 am
June 20, 2024
Marigold Health secures $11 million for AI-enabled peer support platform for mental health and substance use disorders.
10:28 am
June 19, 2024
At AWE2024 in Long Beach, California, Fundamental VR announced it incorporated AI into its surgical training platform and HouseCall VR relayed it has signed an agreement with the University of Georgia College of Pharmacy.
11:02 am
June 17, 2024
Tx-LLM was fine-tuned from Google's Med-PaLM 2 and created to analyze a variety of chemical or biological entities to assist with the drug-discovery pipeline.
10:48 am
June 14, 2024
The telemedicine company's clinical president and its founder and CEO allegedly participated in a scheme to profit from providing easy access to Adderall for no valid medical purpose.
